Are we ready for CD19-targeted CAR T-cell therapies in MS?

被引：3
|
作者：
Giovannoni, Gavin [1 ,6 ]
Hawkes, Christopher H. [1 ]
Lechner-Scott, Jeannette [2 ]
Levy, Michael [3 ,4 ]
Yeh, E. Ann [5 ]
机构：
[1] Queen Mary Univ London, Blizard Inst, Fac Med & Dent, London, England
[2] Univ Newcastle, Newcastle, Australia
[3] Massachusetts Gen Hosp, Boston, MA USA
[4] Harvard Med Sch, Boston, MA USA
[5] Univ Toronto, Dalla Lana Sch Publ Hlth, Dept Paediat, Toronto, ON, Canada
[6] Queen Mary Univ London, Fac Med & Dent, London, England
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2023年 / 70卷
关键词：
Chimeric antigen receptors T-cells; CAR T-cells; Systemic lupus erythematosus;
D O I：
10.1016/j.msard.2023.104590
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
    Gust, Juliane
    Taraseviciute, Agne
    Turtle, Cameron J.
    CNS DRUGS, 2018, 32 (12) : 1091 - 1101
  • [2] Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
    Juliane Gust
    Agne Taraseviciute
    Cameron J. Turtle
    CNS Drugs, 2018, 32 : 1091 - 1101
  • [3] Understanding Outcomes of CD19-Targeted CAR T Cell Immunotherapy
    Turtle, Cameron J.
    BLOOD, 2017, 130
  • [4] Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
    Shadman, Mazyar
    Gauthier, Jordan
    Hay, Kevin A.
    Voutsinas, Jenna M.
    Milano, Filippo
    Li, Ang
    Hirayama, Alexandre V.
    Sorror, Mohamed L.
    Cherian, Sindhu
    Chen, Xueyan
    Cassaday, Ryan D.
    Till, Brian G.
    Gopal, Ajay K.
    Sandmaier, Brenda M.
    Maloney, David G.
    Turtle, Cameron J.
    BLOOD ADVANCES, 2019, 3 (20) : 3062 - 3069
  • [5] CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
    Park, Jae H.
    Geyer, Mark B.
    Brentjens, Renier J.
    BLOOD, 2016, 127 (26) : 3312 - 3320
  • [6] Late Effects of CD19-Targeted CAR-T Cell Therapy
    Cordeiro, Ana
    Bezerra, Evandro D.
    Hill, Joshua Aiden
    Turtle, Cameron J.
    Maloney, David G.
    Bar, Merav
    BLOOD, 2018, 132
  • [7] Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphoma
    Carniti, Cristiana
    Caldarelli, Nicole M.
    Agnelli, Luca
    Torelli, Tommaso
    Ljevar, Silva
    Jonnalagadda, Sadhana
    Zanirato, Giada
    Fardella, Eugenio
    Stella, Federico
    Lorenzini, Daniele
    Brich, Silvia
    Arienti, Flavio
    Dodero, Anna
    Chiappella, Annalisa
    Magni, Martina
    Corradini, Paolo
    BLOOD ADVANCES, 2024, 8 (08) : 1968 - 1980
  • [8] Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing
    Chen, Gregory M.
    Chen, Chia-Hui
    Perazzelli, Jessica
    Grupp, Stephan A.
    Barrett, David M.
    Tan, Kai
    CANCER IMMUNOLOGY RESEARCH, 2023, 11 (01) : 13 - 19
  • [9] Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy
    Lamure, Sylvain
    Van Laethem, Francois
    De Verbizier, Delphine
    Lozano, Claire
    Gehlkopf, Eve
    Tudesq, Jean-Jacques
    Serrand, Chris
    Benzaoui, Mehdi
    Kanouni, Tarik
    Quintard, Adeline
    De Vos, John
    Tchernonog, Emmanuelle
    Platon, Laura
    Ayrignac, Xavier
    Ceballos, Patrice
    Sirvent, Anne
    Francois, Mickael
    Guedon, Hanane
    Quittet, Philippe
    Mongellaz, Cedric
    Conte, Aurelie
    Herbaux, Charles
    Bret, Caroline
    Taylor, Naomi
    Dardalhon, Valerie
    Cartron, Guillaume
    CANCERS, 2021, 13 (17)
  • [10] CD19-targeted CAR T cells in refractory antisynthetase syndrome
    Mueller, Fabian
    Boeltz, Sebastian
    Knitza, Johannes
    Aigner, Michael
    Voelkl, Simon
    Kharboutli, Soraya
    Reimann, Hannah
    Taubmann, Jule
    Kretschmann, Sascha
    Roesler, Wolf
    Manger, Bernhard
    Wacker, Jochen
    Mougiakakos, Dimitrios
    Jabari, Samir
    Schroeder, Rolf
    Uder, Michael
    Roemer, Frank
    Kroenke, Gerhard
    Mackensen, Andreas
    Schett, Georg
    LANCET, 2023, 401 (10379): : 815 - 818
12345